Real-life outcomes of apremilast therapy in patients with psoriasis

Summaries 3 min 307

Font Size

Created On: 05/08/2021

Real-life outcomes of apremilast therapy in patients with psoriasis

This study examined the real-life outcomes of apremilast in patients with psoriasis (selective phosphodiesterase-4 inhibitor) in routine practice.

See All

Key take away

This longitudinal study comprising 159 patients with psoriasis and psoriatic arthritis showed apremilast to be an effective and safe therapy for improving skin condition and lower psoriasis severity.

Background

This study examined the real-life outcomes of apremilast in patients with psoriasis (selective phosphodiesterase-4 inhibitor) in routine practice.

Method

One hundred and fifty-nine individuals (90 men) with plaque psoriasis were included. Out of these, 31% of the patients had psoriatic arthritis. At the time of enrollment, all the individuals initiated apremilast.

Result

During the course of 12 months, noticeable improvement in Dermatology Life Quality Index scores, body surface area, and Psoriasis Area and Severity Index was observed. However, there were no changes in improvement considering the body mass index (BMI). Lack of response led to the withdrawal of apremilast in 10.6% of the patients.